Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction

Lihong Shi, Shuaiying Cui, James D. Engel, Osamu Tanabe

Research output: Contribution to journalArticlepeer-review

126 Citations (Scopus)


Enhanced fetal γ-globin synthesis alleviates symptoms of β-globinopathies such as sickle cell disease and β-thalassemia, but current γ-globin-inducing drugs offer limited beneficial effects. We show here that lysine-specific demethylase 1 (LSD1) inhibition by RNAi in human erythroid cells or by the monoamine oxidase inhibitor tranylcypromine in human erythroid cells or β-type globin-transgenic mice enhances γ-globin expression. LSD1 is thus a promising therapeutic target for γ-globin induction, and tranylcypromine may serve as a lead compound for the development of a new γ-globin inducer.

Original languageEnglish
Pages (from-to)291-294
Number of pages4
JournalNature Medicine
Issue number3
Publication statusPublished - 2013 Mar
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction'. Together they form a unique fingerprint.

Cite this